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Abstract
Clostridioides difficile infections are a significant threat to our healthcare system, and rapid and accurate diagnostics are crucial to
implement the necessary infection prevention and control measurements. Nucleic acid amplification tests are such reliable
diagnostic tools for the detection of toxigenic Clostridioides difficile strains directly from stool specimens. In this multicenter
evaluation, we determined the performance of the revogene C. difficile assay. The analysis was conducted on prospective stool
specimens collected from six different sites in Europe. The performance of the revogene C. difficile assay was compared to the
different routine diagnostic methods and, for a subset of the specimens, against toxigenic culture. In total, 2621 valid stool
specimens were tested, and the revogene C. difficile assay displayed a sensitivity/specificity of 97.1% [93.3–99.0] and 98.9%
[98.5–99.3] for identification of Clostridioides difficile infection. Discrepancy analysis using additional methods improved this
performance to 98.8% [95.8–99.9] and 99.6% [99.2–99.8], respectively. In comparison to toxigenic culture, the revogene
C. difficile assay displayed a sensitivity/specificity of 93.0% [86.1–97.1] and 99.5% [98.7–99.9], respectively. These results
indicate that the revogene C. difficile assay is a robust and reliable aid in the diagnosis of Clostridioides difficile infections.
Introduction
Clostridioides difficile infections (CDI), caused by the Gram-pos-
itive, spore-forming anaerobic bacterium Clostridioides difficile
(C. difficile), create a tremendous burden on our healthcare system.
In Europe alone, approximately 124.000–172.000 CDI cases are
identified on a yearly basis, and CDIManagement attributed costs
approach €3.000 million [1–4]. Furthermore, CDI remains
underdiagnosed with approximately 39,000 missed cases yearly,
as reported by the EUCLID study, due to unawareness of the
condition, unawareness of when to request a CDI test and nonop-
timal testing strategies [5, 6]. Therefore, the trueCDI burden on the
healthcare system remains unknown. However, together with the
emergence of hypervirulent C. difficile strains (e.g., 027/NAP1
strain), this CDI problematic has fueled the development of (i)
new technologies for diagnosing CDI, (ii) new therapeutic strate-
gies, and (iii) optimized protocols for CDI infection prevention and
control, to reduce the CDI-associated healthcare burden [7, 8].
To better understand the complex CDI problem, the European
Society of Clinical Microbiology and Infectious Diseases
(ESCMID) established a workgroup of international experts to
define uniform European guidelines. Importantly, these guide-
lines provide detailed diagnostic guidance for routine detection
ofC. difficile [9]. Recently, the guidelines were updated to incor-
porate more novel technological developments, specifically to
cover the expansion in available nucleic acid amplification tech-
niques (NAAT) [10]. Overall, it was concluded that a two-step
algorithm, consisting of a highly sensitive screening test followed
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by a more specific confirmatory test detecting free toxins, is
required because stand-alone methods failed to reach adequate
positive predictor values [10]. In addition, the inability to differ-
entiate CDI patients fromC. difficile carriers when testing for the
presence of a toxigenic strain rather than free toxins further lim-
ited the use of certain stand-alone techniques. Further, defining
optimal diagnostic pathways requires the incorporation of both
the performance and the effectiveness of testing (i.e., time to
result, workflow, etc.). However, it remains difficult to quantify
these aspects, and often there is a lack of sufficient literature data.
Nonetheless, toxigenic culture and cell culture cytotoxicity neutral-
ization assay (CCNA) were identified as not suitable for routine
application due to their complexity and long turnaround time [11].
In parallel with the emergence of European CDI guidelines,
the healthcare system has been steadily restructuring. The up-
coming trend (as described by the WHO) of both centraliza-
tion and decentralization arose from continuous pressure on
the healthcare system due to aging of the population and the
economic restraints on the health sector. This restructuring has
since fueled the emergence of larger centralized laboratories,
serving multiple hospitals simultaneously, to improve the ef-
ficiency of laboratory testing. However, a centralized lab en-
vironment has the disadvantage that it creates a delay in result
reporting due to the requirement of specimen transport. This
opens the door for the implementation of more advanced tech-
nologies. With respect to CDI, the delay to result imposed by
transport of the specimen to the laboratory followed by a mul-
tistep diagnostic approach in the laboratory might be detri-
mental to CDI outcome [12]. This does not only impact infec-
tion prevention and control measurements but proper patient
management in general. Recent reports regarding the increase
in CDI incidence hint toward an unresolved issue and the need
for further improvement in the efficiency of CDI diagnostics
and infection prevention and control measurements [13–15].
In contrast to the centralization of lab infrastructure, a sep-
arate and opposite field of point-of-care testing (POCT) has
emerged simultaneously. One of the purposes of POCT plat-
forms is to decentralize certain parts of central laboratory test-
ing to reduce time to result and improve clinical decision
making. Here, we report the results of a multicenter study in
Europe for identification of toxigenic C. difficile strains using
a new molecular platform called revogene™ from GenePOC
Inc. (Quebec, Canada), recently acquired by Meridian
Biosciences, that might suit as POCT platform with the right
test menu in the future.
Methods
Study design
From January to December 2017, the manufacturer coordinat-
ed the data collection and analysis of different local
microbiology laboratories and national and/or regional refer-
ence laboratories for Clostridioides difficile across Europe. In
total, six laboratories (representatives of the following coun-
tries: (i) France, (ii) the Netherlands, (iii) Belgium, (iv) the
UK, (v) Switzerland, and (vi) Italy) participated in this study
with the purpose of evaluating the revogene™ C. difficile as-
say (abbreviated to “revogene” in the data analysis) in com-
parison to their routine diagnostic methods. The different lab-
oratories were unaware of the participation of the other labo-
ratories for the duration of their study. The participating labo-
ratories were carefully chosen to obtain sufficient data from
various CDI approaches used in Europe for detection of toxi-
genic C. difficile and CDI. The difference in the workflows
used as reference was necessary for a well-rounded evaluation
of the system, considering the gold standard ESCMID defined
for CDI identification is different from the algorithm it recom-
mends for actual CDI diagnosis, as it is too slow [9, 10]. This
particular site selection therefore allowed a performance eval-
uation in terms of accuracy of identification both in the abso-
lute and within a time-sensitive frame.
All evaluation sites collected unformed stool specimens, in
a prospective manner, from their routine for the duration of
their respective study. Routine testing was mostly performed
in parallel to the revogene assay to avoid any bias as conse-
quence of prolonged specimen storage. Collection, transport,
and handling of the stool specimens occurred according to the
local guidelines while in accordance with the specifications of
the different manufacturers. For all the evaluation sites, the
manufacturer provided the necessary equipment to work with
the revogene C. difficile assay.
Of note, in Switzerland, two distinct sites participated in the
study design: (i) Bioanalytica (oversaw datamanagement) and
(ii) Lucerne Cantonal Hospital (all specimens were
transported to Bioanalytica for testing with the revogene,
which was performed within 5 days of original specimen col-
lection). Furthermore, Bioanalytica collected stool specimens
from two subpopulations of patients: (i) patients suspected of
CDI and (ii) outpatients not suspected of CDI. For the latter
population, stool specimens from outpatients with a negative
BD MAX™ Enteric Bacterial panel (BD) were selected for
testing. The epidemiological findings of this investigation fall
outside the scope of this publication. However, all specimens
were tested with the proper methodology to be included in the
performance calculations.
Definitions
As none of the microbiology laboratories used exactly the
same methodology, either due to the fact that they used differ-
ent CDI diagnostics algorithms or diagnostic tests from differ-
ent manufacturers, general definitions were put in place to
standardize the data analysis. Two main definitions were
adopted: (i) CDI cases and (ii) C. difficile carriers (or
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“carriers” in short). A CDI case was defined when free toxin
was detected directly from stool specimens. A C. difficile car-
rier was defined by the presence of a toxigenic strain in stools
without any detectable free toxin.
For two sites (France and the Netherlands), the gold stan-
dards used to define CDI cases and C. difficile carriers were,
respectively, CCNA and toxigenic culture, in accord with
ESCMID guidelines [9, 10]. As for the remaining four sites
(the UK, Belgium, Switzerland, and Italy), all used as gold
standard different variations of the diagnostic algorithm cur-
rently recommended as a suitable, faster alternative to CCNA
and toxigenic culture [10]. In general, stool samples found
positive for toxin A/B to enzyme immunoassay (EIA) were
considered CDI cases. On the other hand, C. difficile carriers
were defined for EIA-negative specimens in which either the
presence of toxin genes could be demonstrated through NAAT
testing or toxigenic culture–proved positive.
A detailed overview of the different testing algorithms and
commercial tests used at the different sites is provided in
Table 1.
Discrepancy analysis
In case of discrepant results between the revogene and the
routine methodology (and/or golden standard method), addi-
tional testing was performed. Table 1 provides an overview of
the methodology used to resolve the discrepancies at each site
(when available).
Data analysis and statistics
Sensitivity, specificities, and positive and negative predictive
values are expressed as percentages. Confidence intervals
were determined with Clopper-Pearson method.
Results
Inclusion rate and valid results
A total of 2662 unformed stool specimens were prospectively
collected and tested with their routine CDI diagnostic algo-
rithm, in parallel with the revogene, across six different eval-
uation sites in Europe. A total of 41 specimens (1.5%) were
excluded from further analysis of which 21 (0.79%) due to
invalid revogene results, 2 (0.08%) due to testing of external
controls, 7 (0.26%) due to not in agreement with the manu-
facturer’s specifications, and 11 (0.41%) due to lack of suffi-
cient reference data. For the 2621 specimens that were includ-
ed in the analysis, 4.2% displayed an unresolved/
indeterminate result with the revogene assay on initial testing,
but after repetition, all specimens gave a valid result. Ta
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Site by site results
Table 2 provides a detailed overview of the performance char-
acteristics for each site that participated in the multicenter
study for identification of (i) CDI and (ii) tcdB+ strains, which
is the sum of the number of CDI cases and the number of
C. difficile carriers. Sensitivity/specificity of the revogene
C. difficile assay for identification of CDI fluctuated between
85–100% and 97–100%, respectively. For the identification of
tcdB+ strains, sensitivity/specificity fluctuated between 84–
100% and 96–100%, respectively.
Revogene C. difficile overall performance
Identification of CDI and tcdB+ strains
According to the definitions described in the Methods section,
Fig. 1 provides an overview of pooled performance of the
revogene assay (as stand-alone method) for identification of
CDI cases and tcdB+ strains. Overall, the revogene assay per-
formed well with a sensitivity/specificity of 97.1% [93.3–
99.0] and 98.9% [98.4–99.2] for identifying CDI cases and
91.9% [88.2–94.8] and 98.7% [98.2–99.1] for identifying
Table 2 Study site overview and performance
CDI
Site # Specimens # CDI Study period Sensitivity [95% CI] Specificity [95% CI]
FR 308 19 01–03 2017 100% [82.4 – 100] 99.7% [98.1 – 100]
NL 386 25 01–04/2017 96.0% [79.7 – 99.9] 98.9% [97.2 – 99.7]
UK 296 15 01–06/2017 100% [78.2 – 100] 98.2% [95.9 – 99.4]
BE 189 22 08–11/2017 90.9% [70.8 – 98.9] 97.6% [94.0 – 99.3]
CH1 232 22 03–09/2017 100% [84.6 – 100] 100% [98.3 – 100]
CH2 504 5 06–09/2017 100% [47.8 – 100] 99.6% [98.6 – 99.6]
CH3 298 14 03–06/2017 85.7% [57.2 – 98.2] 98.6% [96.4 – 99.6]
IT 408 48 09–11/2017 100% [92.6 – 100] 98.3% [96.4 – 99.4]
tcdB+ strains
Site # Specimens # tcdB+ Study period Sensitivity [95% CI] Specificity [95% CI]
FR 308 35 01–03/2017 91.4% [76.9 – 98.2] 99.6% [98.0 – 99.9]
NL 386 28 01–04/2017 89.3% [71.8 – 97.7] 98.9% [97.2 – 99.7]
UK 296 43 01–06/2017 95.3% [84.2 – 99.4] 98.0% [95.5 – 99.4]
BE 189 36 08–11/2017 86.1% [70.5 – 95.3] 96.1% [91.7 – 98.6]
CH1 232 38 03–09/2017 100% [90.8 – 100] 100% [98.1 – 100]
CH2 504 11 06–09/2017 100% [47.8 – 100] 99.6% [98.5 – 99.5]
CH3 298 19 03–06/2017 84.2% [60.4 – 96.6] 98.6% [96.4 – 99.6]
IT 408 89 09–11/2017 91.0% [83.1 – 96.0] 98.1% [96.0 – 99.3]
FR France; NL the Netherlands; UK the United Kingdom; BE Belgium; CH Switzerland; IT Italy. The numbering 1 to 3 for Switzerland reflects the
different evaluations setup as described in the Method section (i.e., Bioanalytica, patients suspected of CDI; Bioanalytica, outpatients not suspected of
CDI; and Lucerne Cantonal hospital, respectively). Sensitivities/specificities are reported with their respective 95% confidence interval (CI)
CDI Clostridioides difficile infection; tcdB+, a Clostridioides difficile identified to carry the tcdB gene
Fig. 1 Overall performance characteristics of the revogene assay for
identification of CDI and tcdB+ strains. a Performance characteristics of
revogene for identifying CDI cases. *15/26 false positives were found to
also be positive with additional techniques as described in the method
section. **3/5 false negatives were also found to be negative using the
same discrepancy analysis. b Performance characteristics of revogene for
identifying tcdB+ strains. ^16/28 false positives were found to be a true
positive after discrepancy analysis as described in the method section.
°11/24 false negatives were confirmed as true negative using the same
discrepancy analysis
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tcdB+ strains. After resolving discrepancies with additional
testing, the sensitivity/specificity improved to 98.8% [95.8–
99.9] and 99.6% [99.2–99.8] for identifying CDI cases and to
95.7% [92.8–97.7] and 99.4% [99.0–99.8] for identification
of tcdB+ stains.
Comparison to toxigenic culture
Three of the six evaluation sites performed toxigenic culture
on all specimens tested which allowed us to compare the
revogene assay against this gold standard method (Fig. 2).
Overall, the revogene assay performed well with sensitivity/
specificity of 90.4% [82.6–95.5] and 98.5% [97.4–99.2], re-
spectively. This performance corresponded to a positive and
negative predictive value (PPV/NPV) of 87.6% [80.1–92.3]
and 98.9% [97.9–99.4], respectively, with a reported overall
prevalence of 10.6% [8.7–12.9]. After resolving the discrep-
ancies, the sensitivity, specificity, PPV, and NPV improved to
93.0 [86.1–97.1], 99.5 [98.7–99.9], 95.9 [89.7–98.4], and
99.1% [98.2–99.6], respectively.
Revogene assay as part of a multistep algorithm
In the above analysis, the revogene performance is determined
as stand-alone method against the reference method.
However, the European Society of Clinical Microbiology
and Infectious Diseases (ESCMID) does not recommend the
use of a single commercial test as stand-alone test for diag-
nosing CDI [9]. Therefore, we extended our data analysis to
incorporate the revogene assay as part of a multistep (i.e., two-
or optional three-steps) algorithm, with the revogene assay
either at the (i) front of the algorithm, to be tested on all
specimens (i.e., revogene -TOX), or (ii) at the end of the al-
gorithm, as confirmatory test (GDH-TOX-revogene).
Overall, the revogene-TOX algorithm performed well with
a sensitivity/specificity of 96.8% [92.1–99.1] and 100%
[99.8–100] for identifying CDI cases and 92.2% [88.0–95.3]
and 98.6% [98.0–99.1] for identifying tcdB+ strains (Fig. 3).
Resolution of the discrepancies improved the sensitivity/
specificity performance to 97.6% [93.2–99.5] and 100% for
identifying CDI cases and 95.8% [92.4–98.0] and 99.3%
[98.8–99.7] for identifying tcdB+ strains. On the other hand,
the GDH-TOX-revogene algorithm performed similarly with
a sensitivity/specificity of 100% [97.1–100] and 100% [99.8–
100] for identifying CDI cases and 89.6% [85.1–93.2] and
99.8% [99.4–99.9] for identifying tcdB+ strains (Fig. 4).
Resolution of the discrepancies improved the sensitivity/
specificity performance to 92.0% [87.8–95.1] and 99.9%
[99.7–100] for identifying tcdB+ strains.
Discussion
Despite significant effort and various strategies to improve
CDI diagnostics, C. difficile remains a global healthcare bur-
den that keeps challenging all stakeholders, from nurse to
clinical microbiologist, to improve in their current field to
overcome this global threat. At the beginning of the century,
molecular biology techniques opened the door to improved
diagnostics, but despite the enormous progressionmade in that
Fig. 3 Overall performance characteristics of the revogene-TOX algo-
rithm. a Performance characteristics of revogene-TOX algorithm for
identifying CDI cases. **1/4 false negatives were confirmed as true neg-
ative using the discrepancy analysis. b Performance characteristics of
revogene-TOX algorithm for identifying tcdB+ strains. ^12/23 false pos-
itives were found to be a true positive after discrepancy analysis as de-
scribed in the method section. °8/18 false negatives were confirmed as
true negative using the same discrepancy analysis
Fig. 2 Overall performance characteristics of the revogene assay in
comparison to toxigenic culture. a Performance characteristics of
revogene with: *8/12 false positives were found to be a true positive
after discrepancy analysis as described in the method section. **2/9
false negatives were confirmed as true negative using the same
discrepancy analysis
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field, molecular diagnostic techniques (like NAAT) remain
underutilized when it comes to diagnosing CDI. Recently, the
amount of available molecular NAAT assays for detection of
CDI have vastly expanded which made the technology more
accessible, especially in the central laboratory, and competitive
in terms of pricing. However, with the emergence of POCT
testing, NAAT technology for infectious diseases is now also
more accessible to smaller labs, or it could be used to equip
satellite labs connected to a central lab for urgent testing. In this
work, we report the results from a multicenter Clostridioides
difficile study that assessed the performance of a novel molecular
platform (i.e., revogene™) from Meridian Biosciences Canada
Inc. (Quebec, Canada). The revogene assay targets the tcdB gene
of toxigenicC. difficile and required minimal hands-on time, and
results were available in approximately an hour. The 1 to 8 flex-
ible throughput combined with the ease of use would allow this
platform to be implemented in both small satellite and central
labs.
In this multicenter study, the revogene assay was capable of
adequately identifying CDI cases and tcdB+ strains. However,
current diagnostic guidelines in Europe recommend to per-
form a two-step algorithm for the identification of CDI cases
[10]. In contrast, the recently updated clinical practice guide-
lines for CDI (by the IDSA and SHEA societies) state that it
would be acceptable to use a stand-alone NAAT assay for
diagnosis CDI under the condition that pre-defined criteria
for stool specimen submission are used by clinicians and lab-
oratory personnel [16]. Interestingly, here, we only observed
minor differences between the revogene assay (stand-alone)
and revogene-TOX algorithm in terms of correctly identifying
CDI cases and tcdB+ strains. Due to the fact that in both
scenarios (i.e., revogene and revogene-TOX) the same dataset
was analyzed with the same definition for CDI cases and
tcdB+ carriers, this might raise doubt on the usefulness of
the confirmatory TOX test in such a two-step algorithm.
However, it must be noted that the absence of the TOX test
would not allow differentiation of CDI from asymptomatic
carriage of C. difficile. When comparing the revogene-TOX
and GDH-TOX-revogene algorithm, we also only observed
some minor differences in performance which raises the gen-
eral question about how to best define the balance between
algorithm performance and time to result. However, this topic
falls out of the scope of the current work, and additional re-
search is required to answer this question.
A major strength of this work was the multicenter approach
that allowed us to (i) capture data on the different C. difficile
diagnostic methodologies used across Europe and (ii) gather
an extensive dataset to determine the performance character-
istics of the revogene assay. The work was further strength-
ened due to standardization of the dataset through the use of
definitions for CDI and tcdB+ strains. This allowed us to com-
pare different diagnostic algorithms for CDI under the same
conditions. However, the fact that different CDI diagnostic
methodologies were used and standardization of the data
was required also imposes a limitation to the study as the
results cannot be extrapolated and properly compared to the
current available literature.
An added value of this system is a decrease in the turn-
around time (TAT): This was extremely significant in the
Belgian and French sites (23–47-h reduction), which are ref-
erence centers where culturing is conducted for epidemiolog-
ical reasons; nonetheless, sites which already used workflows
considered time-accurate for CDI diagnosis showed a de-
crease in TAT, if less marked (1 h for the Netherlands and
Switzerland, 2 h for Italy and UK).
In conclusion, the revogene C. difficilemolecular assay for
detection of the tcdB gene of toxigenic Clostridioides difficile
is a high quality and simple to use diagnostic test providing
reliable results in approximately an hour. This makes the
revogene assay suitable for implementation as diagnostic util-
ity, either as frontline/confirmatory test in a multistep algo-
rithm or as stand-alone method if used with proper institution-
al criteria for collection of CDI-suspected stool specimens.
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